- Investing Ideas
- Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
8
Companies with a Value score of at least 3, ordered by Value score
8 companies
Bavarian Nordic
Market Cap: DKK 13.5b
Develops, manufactures, and supplies life-saving vaccines.
BAVA
DKK 176.40
7D
-0.8%
1Y
-25.8%
H. Lundbeck
Market Cap: DKK 40.0b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN B
DKK 41.58
7D
0.2%
1Y
19.3%
Novo Nordisk
Market Cap: DKK 1.3t
Engages in the research and development, manufacture, and distribution of pharmaceutical products.
NOVO B
DKK 305.10
7D
-0.5%
1Y
-5.6%
H. Lundbeck
Market Cap: DKK 40.0b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN A
DKK 35.55
7D
-1.3%
1Y
19.9%
Genmab
Market Cap: DKK 119.3b
A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
GMAB
DKK 1,999.00
7D
7.6%
1Y
44.6%
Gubra
Market Cap: DKK 5.9b
A disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally.
GUBRA
DKK 362.80
7D
-6.2%
1Y
1.6%
ALK-Abelló
Market Cap: DKK 49.6b
An allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally.
ALK B
DKK 224.00
7D
0.9%
1Y
25.8%
Strategic Partners
Market Cap: DKK 30.4m
Does not have significant operations.
STRAP
DKK 730.00
7D
5.8%
1Y
-33.0%